Subscribe
Brent C. James, MD, MStat, Executive Director and Quality Officer, Intermountain Health­care Leadership Institute, Salt Lake City, UT delivered the Presidential lecture at the 2016 American Academy of Neurology annual meeting.

A cost-effectiveness analysis of relapsing-remitting multiple sclerosis (MS) therapies has shown the importance of using first-line treatments first to treat the disease. In terms of achieving no evidence of disease activity (NEDA), the most effective treatment strategy was natalizumab in the first-line setting, followed by alemtuzumab as first-line treatment, according to a presentation at the 2016 American Academy of Neurology annual meeting.

Neurologist-directed ambulatory care for chronic neurologic diseases resulted in higher costs but fewer adverse events and less use of acute care services, according to an American Academy of Neurology–supported study.

Results 1 - 3 of 3
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology